Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B

References

• PowellJSRodgersGMInherited coagulation disordersGreerJPArberDAGladerBWintrobe’s Clinical HematologyPhiladelphia, PAWolters Kluwer201411431185
   Google Scholar
• GiangrandePHaemophilia B: Christmas diseaseExpert Opin Pharmacother2005691517152416086639
   PubMed Web of Science ®Google Scholar
• MannucciPMMendolicchioLGringeriAUse of prophylaxis to prevent complications of hemophiliaAdv Exp Med Biol2001489596411554591
   PubMed Web of Science ®Google Scholar
• NilssonIMBerntorpELofqvistTPetterssonHTwenty-five years’ experience of prophylactic treatment in severe haemophilia A and BJ Intern Med1992232125321640190
   PubMed Web of Science ®Google Scholar
• Manco-JohnsonMJAbshireTCShapiroADProphylaxis versus episodic treatment to prevent joint disease in boys with severe hemophiliaN Engl J Med2007357653554417687129
   PubMed Web of Science ®Google Scholar
• DarbySCKanSWSpoonerRJMortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIVBlood2007110381582517446349
   PubMed Web of Science ®Google Scholar
• WhiteGC2ndCourterSBrayGLLeeMGompertsEDA multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia AThromb Haemost19977746606679134639
   PubMed Web of Science ®Google Scholar
• FeldmanBMPaiMRivardGETailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis StudyJ Thromb Haemost2006461228123616706965
   PubMed Web of Science ®Google Scholar
• HackerMRGeraghtySManco-JohnsonMBarriers to compliance with prophylaxis therapy in haemophiliaHaemophilia20017439239611442644
   PubMed Web of Science ®Google Scholar
• Manco-JohnsonMJRiskeBKasperCKAdvances in care of children with hemophiliaSemin Thromb Hemost200329658559414719175
   PubMed Web of Science ®Google Scholar
• GaterAThomsonTAStrandberg-LarsenMHaemophilia B: impact on patients and economic burden of diseaseThromb Haemost2011106339840421833450
   PubMed Web of Science ®Google Scholar
• NathwaniACTuddenhamEGRangarajanSAdenovirus-associated virus vector-mediated gene transfer in hemophilia BN Engl J Med2011365252357236522149959
   PubMed Web of Science ®Google Scholar
• NegrierCKnobeKTiedeAGiangrandePMossJEnhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia BBlood2011118102695270121555744
   PubMed Web of Science ®Google Scholar
• MartinowitzUShapiroAQuonDVPharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysisHaemophilia201218688188722764744
   PubMed Web of Science ®Google Scholar
• ShapiroADRagniMVValentinoLARecombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a Phase I/IIa study in hemophilia B patientsBlood2012119366667222110246
   PubMed Web of Science ®Google Scholar
• MetznerHJPipeSWWeimerTSchulteSExtending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albuminThromb Haemost2013110593193924178510
   PubMed Web of Science ®Google Scholar
• PetersRTLowSCKamphausGDProlonged activity of factor IX as a monomeric Fc fusion proteinBlood2010115102057206420056791
   PubMed Web of Science ®Google Scholar
• SantagostinoENegrierCKlamrothRSafety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patientsBlood2012120122405241122859609
   PubMed Web of Science ®Google Scholar
• SchmidtSRFusion-proteins as biopharmaceuticals – applications and challengesCurr Opin Drug Discov Devel2009122284295
   PubMedGoogle Scholar
• HuangCReceptor-Fc fusion therapeutics, traps, and MIMETIBODY technologyCurr Opin Biotechnol200920669269919889530
   PubMed Web of Science ®Google Scholar
• BorelYFritscheRBorelHDahlgrenUDalhman-HoglundAHansonLAParenteral and oral administration of tolerogens: protein–IgG conjugatesAnn N Y Acad Sci199677880878611019
   PubMed Web of Science ®Google Scholar
• BorelHBorelYA novel technique to link either proteins or peptides to gammaglobulin to construct tolerogensJ Immunol Methods199012621591682154521
   PubMed Web of Science ®Google Scholar
• RoopenianDCAkileshSFcRn: the neonatal Fc receptor comes of ageNat Rev Immunol20077971572517703228
   PubMed Web of Science ®Google Scholar
• RathTBakerKDumontJAFc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeuticsCrit Rev Biotechnol Epub20131024
   PubMed Web of Science ®Google Scholar
• KontermannREStrategies for extended serum half-life of protein therapeuticsCurr Opin Biotechnol201122686887621862310
   PubMed Web of Science ®Google Scholar
• LussonJVieauDHamelinJDayRChretienMSeidahNGcDNA structure of the mouse and rat subtilisin/kexin-like PC5: a candidate proprotein convertase expressed in endocrine and nonendocrine cellsProc Natl Acad Sci U S A19939014669166958341687
   PubMed Web of Science ®Google Scholar
• BondMJankowskiMPatelHBiochemical characterization of recombinant factor IXSemin Hematol1998352 Suppl 211179565161
   PubMed Web of Science ®Google Scholar
• LissitchkovTMatysiakMZavilskaKHead-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia BHaemophilia201319567467823647607
   PubMed Web of Science ®Google Scholar
• PowellJSPasiKJRagniMVPhase 3 study of recombinant factor IX Fc fusion protein in hemophilia BN Engl J Med2013369242313232324304002
   PubMed Web of Science ®Google Scholar
• LambertTRechtMValentinoLAReformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia BHaemophilia200713323324317498071
   PubMed Web of Science ®Google Scholar
• RothDAKesslerCMPasiKJRupBCourterSGTubridyKLHuman recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentratesBlood200198133600360611739163
   PubMed Web of Science ®Google Scholar
• van den BergHMFischerKvan der BomJGComparing outcomes of different treatment regimens for severe haemophiliaHaemophilia20039Suppl 1273112709034
   PubMed Web of Science ®Google Scholar
• LillicrapDImprovements in factor concentratesCurr Opin Hematol201017539339720613509
   PubMed Web of Science ®Google Scholar
• HoffmanMWhinnaHCMonroeDMCirculating tissue factor accumulates in thrombi, but not in hemostatic plugsJ Thromb Haemost2006492092209316961625
   PubMed Web of Science ®Google Scholar
• CarlssonMBjorkmanSBerntorpEMultidose pharmacokinetics of factor IX: implications for dosing in prophylaxisHaemophilia19984283889873843
   PubMed Web of Science ®Google Scholar
• KiskerCTEisbergASchwartzBProphylaxis in factor IX deficiency product and patient variationHaemophilia20039327928412694518
   PubMed Web of Science ®Google Scholar
• BjorkmanSProphylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspectiveHaemophilia20039Suppl 110110812709045
   PubMed Web of Science ®Google Scholar
• AhnstromJBerntorpELindvallKBjorkmanSA 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophiliaHaemophilia200410668969715569163
   PubMed Web of Science ®Google Scholar
• WeismanRBiogen Idec prices its newly approved hemophilia drugThe Boston Globe2014419
   Google Scholar
• SkinnerMWMylesEWorld Federation of Hemophilia: 50 years of advancing treatment for allHaemophilia201319447548023777531
   PubMed Web of Science ®Google Scholar
• WeimerTWormsbacherWKronthalerULangWLiebingUSchulteSProlonged in-vivo half-life of factor VIIa by fusion to albuminThromb Haemost200899465966718392323
   PubMed Web of Science ®Google Scholar
• SchulteSInnovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIIIThromb Res2013131Suppl 2S2S623537723
   PubMed Web of Science ®Google Scholar
• SantagostinoEPROLONG-9FP clinical development program – Phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP)Thromb Res2013131Suppl 2S7S1023537724
   PubMed Web of Science ®Google Scholar
• MahlanguJPowellJSRagniMVPhase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia ABlood2013123331732524227821
   PubMed Web of Science ®Google Scholar
• ScottDWPrattKPMiaoCHProgress toward inducing immunologic tolerance to factor VIIIBlood2013121224449445623502223
   PubMed Web of Science ®Google Scholar
• GuiTLinHFJinDYCirculating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivoBlood2002100115315812070021
   PubMed Web of Science ®Google Scholar
• AbuchowskiAvan EsTPalczukNCDavisFFAlteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycolJ Biol Chem19772521135783581405385
   PubMed Web of Science ®Google Scholar
• CalicetiPVeroneseFMPharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugatesAdv Drug Deliv Rev200355101261127714499706
   PubMed Web of Science ®Google Scholar
• ShenBWSpeigelPCChangCHThe tertiary structure and domain organization of coagulation factor VIIIBlood200811131240124717965321
   PubMed Web of Science ®Google Scholar
• NgoJCHuangMRothDAFurieBCFurieBCrystal structure of human factor VIII: implications for the formation of the factor IXa–factor VIIIa complexStructure200816459760618400180
   PubMed Web of Science ®Google Scholar
• MeiBPanCJiangHRational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatmentBlood2010116227027920194895
   PubMed Web of Science ®Google Scholar
• HortonSWalshCEmeryPCertolizumab pegol for the treatment of rheumatoid arthritisExpert Opin Biol Ther201212223524922165979
   PubMed Web of Science ®Google Scholar
• AlconcelSNSBaasASMaynardHDFDA-approved poly(ethylene glycol)–protein conjugate drugsPolym Chem20112714421448
   Web of Science ®Google Scholar
• IvensIABaumannAMcDonaldTAHumphriesTJMichaelsLAMathewPPEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregiversHaemophilia2013191112022913770
   PubMed Web of Science ®Google Scholar
• TangLLeongLSimDvon Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivoHaemophilia201319453954523534820
   PubMed Web of Science ®Google Scholar
• CoyleTERedingMTLinJCMichaelsLAShahAPowellJPhase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia AJ Thromb Haemostat2014124488496
   PubMed Web of Science ®Google Scholar
• TurecekPLBossardMJGraningerMBAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional, and structural characterisationHamostaseologie201232Suppl 1S29S3822961422
   PubMed Web of Science ®Google Scholar
• TiedeABrandBFischerREnhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia AJ Thromb Haemost201311467067823398640
   PubMed Web of Science ®Google Scholar
• Novo Nordisk A/SNovo Nordisk reports positive results from first phase 3 trial with N8-GP, a long-acting factor VIII for treatment of haemophilia A [company announcement]BagsværdNovo Nordisk A/S2014 [March 19]. Available from: http://www.novonordisk.com/include/asp/exe_news_attachment.asp?sAttachmentGUID=31c49463-5e29-4262-9e4d-f8c47e96a57bAccessed July 18, 2014
   Google Scholar
• SandbergHKannichtCStenlundPFunctional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIIIThromb Res2012130580881723010293
   PubMed Web of Science ®Google Scholar
• KannichtCRamstromMKohlaGCharacterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIIIThromb Res20131311788823058466
   PubMed Web of Science ®Google Scholar
• SchulteSChallenges for new haemophilia products from a manufacturer’s perspectiveThromb Res Epub20131221
   Web of Science ®Google Scholar
• ZollnerSBRaquetEMuller-CohrsJPreclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIIIThromb Res2013132228028723830969
   PubMed Web of Science ®Google Scholar
• ZollnerSSchuermannDRaquetEPharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)J Thromb Haemost201412222022824641308
   PubMed Web of Science ®Google Scholar
• MutoAYoshihashiKTakedaMAnti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementationJ Thromb Haemostat2014122206213
   Web of Science ®Google Scholar
• HildenILauritzenBSorensonBBHemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia modelBlood2012119245871587822563084
   PubMed Web of Science ®Google Scholar
• AgersoHOvergaardRVPetersonMBPharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in cynomolgus monkeys after iv and sc administrationEur J Pharm Sci201456656924568891
   PubMed Web of Science ®Google Scholar
• GorczycaMENairSCJilmaBInhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasmaJ Thromb Haemost20121081581159022632032
   PubMed Web of Science ®Google Scholar
• PrasadSLillicrapDLabelleAEfficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia ABlood2008111267267917978172
   PubMed Web of Science ®Google Scholar
• KnappeSGorczycaMEJilmaBPlasmatic tissue factor pathway inhibitor is a major determinant of clotting in factor VIII inhibited plasma or bloodThromb Haemost2013109345045723348798
   PubMed Web of Science ®Google Scholar
• PeraramelliSThomassenSHeinzmannADirect inhibition of factor VIIa by TFPI and TFPI constructsJ Thromb Haemost201311470471423347185
   PubMed Web of Science ®Google Scholar
• DockalMHartmannRFriesMSmall peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI)J Biol Chem201428931732174124275667
   PubMed Web of Science ®Google Scholar
• BolligerDSzlamFSuzukiNMatsushitaTTanakaKAHeterozygous antithrombin deficiency improves in vivo haemostasis in factor VIII-deficient miceThromb Haemost201010361233123820352163
   PubMed Web of Science ®Google Scholar
• PeyvandiFGaragiolaISeregniSFuture of coagulation factor replacement therapyJ Thromb Haemost201311Suppl 1849823809113
   PubMed Web of Science ®Google Scholar
• SehgalAVaishnawAFitzgeraldKLiver as a target for oligonucleotide therapeuticsJ Hepatol20135961354135923770039
   PubMed Web of Science ®Google Scholar
• AkincASehgalAHettingerJAn RNAi Therapeutic Targeting Antithrombin Increases Thrombin Generation in Nonhuman Primates Available from: http://www.alnylam.com/web/wp-content/uploads/2012/12/ALNY-ASH-AT3posterXpanel-Dec2012-r.pdfAccessed 18 July, 2014
   Google Scholar
• KonkleBAEbbesenLSErhardtsenERandomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitorsJ Thromb Haemost2007591904191317723130
   PubMed Web of Science ®Google Scholar
• LentzSREhrenforthSKarimFARecombinant factor VIIa analogue in management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfaJ Thromb Haemost Epub2014616
   Web of Science ®Google Scholar
• MahlanguJNKohPLNgHJLissitchkovTHardtkeMSchroederJThe TRUST Trial: Anti-Drug Antibody Formation In a Patient With Hemophilia With Inhibitors After Receiving The Activated Factor VII Product Bay 86-6150Blood201312221573
   Web of Science ®Google Scholar
• ParunovLASoshitovaNPFadeevaOADrug-drug interaction of the anti-TFPI aptamer BAX499 and factor VIII: Studies of spatial dynamics of fibrin clot formation in hemophilia AThrombo Res20141331112119
   PubMed Web of Science ®Google Scholar